Veracity

Market position

Veracity is positioned as a natural, plant-based metabolic health brand competing for demand created by the growth of GLP-1 drugs such as Ozempic. Investor Maveron describes it as a leader in non-pharma, plant-based metabolic health products. It was among the earlier wellness brands to launch a non-drug GLP-1 alternative, ahead of entrants such as Kourtney Kardashian's Lemme. The company cites a global GLP-1 market projected to grow at roughly a 17.5% CAGR to $156.71 billion by 2030, with North America accounting for nearly 78% of it. Veracity was named to BeautyMatter's FUTURE50 2025 list.

The company frames its supplements as "anti-GLP-1s" that treat underlying metabolic causes rather than symptoms, blending Eastern holistic practice with Western clinical science. Stated differentiators include doctor-developed formulations, clinical testing of products, prescription-strength but drug-free natural ingredients, third-party purity testing, and proprietary data from its hormone test used to inform product development.

Technology

Veracity's products combine botanical ingredients with clinical validation, described by the company as medical-grade, drug-free formulations using a 6x potency extraction method, third-party tested for heavy metals and manufactured in the United States in FDA-reviewed, NSF- and GMP-certified facilities. Its Hormone Wellness Test is a saliva-based at-home diagnostic measuring key hormones and pH, and the company says the test has generated more than 10 million unique health data points that inform its formulation work. A quiz-based protocol recommender matches customers to supplement stacks.

Go-to-market

Products are sold through Veracity's own e-commerce site, Amazon and wellness destinations including the acupuncture studio Wthn. Acquisition and merchandising rely on an online protocol quiz, promotional discounting, subscription enrollment, bundled sets and multi-month supply pricing, plus content and social channels.

Consumers, predominantly focused on adults experiencing low energy, weight gain, cravings, brain fog, stress and burnout, gut issues and perimenopause symptoms, and those seeking non-pharmaceutical alternatives to GLP-1 weight-loss drugs.

Geography

Headquartered in New York, NY, with products manufactured in the United States and sold online in the U.S. via its own site and Amazon, plus select wellness retail partners.

History

Veracity launched in 2021 with the Hormone Wellness Test, a saliva diagnostic, and shortly afterwards introduced six skincare products that have since been sunsetted. It raised $5.8 million in 2021. Metabolism Ignite, its supplement positioned as a non-pharmaceutical alternative to GLP-1 drugs, launched roughly mid-2024, sold out within two weeks and became the company's bestseller. In June 2025 Veracity closed a $6 million Series A led by Maveron and Melitas Ventures, bringing cumulative funding to $14 million across three rounds, and appointed Dr. Giorgio Dell'Acqua, previously chief science officer at Nutrafol, as Chief Science Officer.

Risks & controversies

The company's marketing makes clinical and efficacy claims for dietary supplements positioned against prescription GLP-1 medications, an area subject to regulatory scrutiny. Concentration risk is notable: growth is largely attributable to a single product, Metabolism Ignite, and revenue depends heavily on subscription retention. Recurring sold-out listings for several SKUs suggest supply constraints. An earlier skincare line was discontinued.